Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.

MLA

Ahlgren, Göran M., et al. “Docetaxel Versus Surveillance After Radical Prostatectomy for High-Risk Prostate Cancer: Results from the Prospective Randomised, Open-Label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.” European Urology, vol. 73, no. 6, June 2018, pp. 870–76. EBSCOhost, https://doi.org/10.1016/j.eururo.2018.01.012.

APA

Ahlgren, G. M., Flodgren, P., Tammela, T. L. J., Kellokumpu-Lehtinen, P., Borre, M., Angelsen, A., Iversen, J. R., Sverrisdottir, A., Jonsson, E., & Sengelov, L. (2018). Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. European Urology, 73(6), 870–876. https://doi.org/10.1016/j.eururo.2018.01.012

Chicago

Ahlgren, Göran M, Per Flodgren, Teuvo L J Tammela, Pirkko Kellokumpu-Lehtinen, Michael Borre, Anders Angelsen, Jon Reidar Iversen, Asgerdur Sverrisdottir, Eirikur Jonsson, and Lisa Sengelov. 2018. “Docetaxel Versus Surveillance After Radical Prostatectomy for High-Risk Prostate Cancer: Results from the Prospective Randomised, Open-Label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.” European Urology 73 (6): 870–76. doi:10.1016/j.eururo.2018.01.012.